Related Experiment Videos

Factors predicting hyperkalemia in patients with cirrhosis receiving spironolactone

Zaigham Abbas1, Khalid Mumtaz, Abdul Salam

  • 1Department of Medicine, The Aga Khan University Hospital, Karachi. zaigham@akunet.org

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
|July 31, 2003
PubMed

Insights

Patients with cirrhosis on spironolactone therapy face higher hyperkalemia risk with high diuretic doses, persistent edema, ascites, elevated creatinine, and female gender. Careful monitoring is crucial for these high-risk individuals.

Area of Science:

  • Hepatology
  • Nephrology
  • Clinical Pharmacology

Background:

  • Cirrhosis management often involves diuretics like spironolactone.
  • Hyperkalemia is a significant complication of spironolactone therapy in cirrhosis patients.
  • Identifying risk factors for hyperkalemia is crucial for patient safety.

Purpose of the Study:

  • To investigate the key factors contributing to hyperkalemia in patients with cirrhosis receiving spironolactone.
  • To compare characteristics of cirrhotic patients with and without hyperkalemia on spironolactone.

Main Methods:

  • An observational, analytical, case-control study was conducted over six months.
  • 150 hospitalized cirrhosis patients on spironolactone were assessed.
  • Hyperkalemic patients (K > 5 mmol/l) were compared to normokalemic patients based on clinical and laboratory parameters.

Main Results:

  • Hyperkalemic patients exhibited higher blood urea nitrogen, serum creatinine, bilirubin, and advanced cirrhosis (high Pugh score).
  • Lower serum sodium and albumin levels were observed in hyperkalemic patients.
  • Higher spironolactone dosage (>100 mg/day), elevated creatinine (>1.3 mg/dl), persistent ascites/edema, and female gender predicted hyperkalemia.

Conclusions:

  • High-dose spironolactone, persistent ascites and edema, elevated serum creatinine, and female gender are significant risk factors for hyperkalemia in cirrhosis.
  • Close monitoring of electrolytes is essential for cirrhotic patients on spironolactone, especially those with these risk factors.
  • Optimizing diuretic dosage and managing fluid status may mitigate hyperkalemia risk.
Abstract

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Acute Kidney Injury VI: Nursing Management01:22

Acute Kidney Injury VI: Nursing Management

Acute Kidney Injury (AKI) results in an inability to maintain fluid, electrolyte, and acid-base balance. Effective nursing management is critical in improving patient outcomes and includes comprehensive patient assessment and targeted interventions.Comprehensive Patient AssessmentA detailed history collection is essential, focusing on any recent infections, nephrotoxic medication use, or chronic conditions such as hypertension and diabetes that may contribute to AKI. During the physical...